1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: Amgen positions for obesity and diabetes; BMS returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer’s crown?; Japan pharma firms cut jobs; and Sun Pharma seeks GLP-1 partner.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 August 2024, including: Amgen, Inc. positions for obesity and diabetes; Bristol Myers Squibb Company returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer AG’s crown?; Japan pharma firms cut jobs; and Sun Pharmaceutical Industries Ltd. seeks GLP-1 partner. 

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode: 

(Also see "Amgen Gets Into Position For MariTide Development" - Scrip, 6 August, 2024.)

(Also see "BMS Returns TIGIT Bispecific To Agenus Amid Pipeline Reshuffle" - Scrip, 5 August, 2024.)

(Also see "Kerendia Could Be Next Jewel In Bayer's Pharma Crown" - Scrip, 6 August, 2024.)

(Also see "Japan Pharma Layoffs: Takeda And Others Implementing Broad Cuts" - Scrip, 8 August, 2024.)

(Also see "Sun Seeks Partner For GLP-I Asset, Legal Challenge Clouds Alopecia Drug Launch" - Scrip, 5 August, 2024.)

Citeline · Scrip's Five Must-Know Things - 13 August 2024

Open Media

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.